阿托伐他汀联合曲美他嗪对心血瘀阻证患者血清超氧化物歧化酶、丙二醛的影响

目的 探讨阿托伐他汀联合曲美他嗪对心血瘀阻证患者的疗效及对血清超氧化物歧化酶（SOD）、丙二醛（MDA）的影响。方法 选取2012年1月-2017年6月西安北车医院收治的68例心血瘀阻证患者，按治疗方法分成对照组34例、观察组34例。对照组通过口服曲美他嗪片治疗，每次20 mg，每天3次；观察组在此基础上联合阿托伐他汀治疗，20 mg/次，1次/d。两组的疗程均为8周。比较两组治疗后心绞痛的改善情况，治疗前后心绞痛发作次数、每次持续时间，比较两组治疗前后血清SOD活力、MDA含量的变化，比较治疗期间不良反应的发生情况。结果 观察组临床疗效的总有效率是94.12%（32/34），显著高于对照组的82.35%（28/34），差异有统计学意义（P<0.05）。两组治疗后心绞痛发作次数及每次持续时间均较治疗前显著下降（P<0.05），且观察组明显低于对照组（P<0.05）。两组治疗后血清SOD活力显著升高（P<0.05），MDA含量显著降低（P<0.05），且观察组比对照组更明显（P<0.05）。治疗期间，两组均未发生严重的不良反应。结论 阿托伐他汀联合曲美他嗪治疗心血瘀阻证疗效确切，安全可靠，可能与有效提高血清SOD活力、降低血清MDA含量有关。

Effects of serum SOD and MDA of atorvastatin combined with trimetazidine in the treatment of patients with coronary heart disease and angina pectoris

Objective To explore the clinical efficacy of atorvastatin combined with trimetazidine in the treatment of patients with coronary heart disease angina pectoris stasis syndrome, and its effects of serum SOD and MDA. Methods Selected 68 patients with coronary heart disease angina pectoris stasis syndrome in our hospital from January 2014 to June 2017. All patients were divided into control group and observation group by treatment methods, each of group of 34 cases. The control group was treated with trimetazidine on the basis of routine treatment. The observation group was treated with atorvastatin on basis of control group. The clinical efficacy, times of angina pectoris episodes, duration of angina pectoris episodes, serum SOD activity and MDA content, and the occurrence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was 94.12% (32/34), which was significantly higher than that in the control group (82.35%, 28/34) (P<0.05). The times of angina pectoris episodes and duration of angina pectoris episodes of two groups were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than the control group (P<0.05). After treatment, serum SOD activity was significantly increased (P<0.05), MDA content was significantly lower (P<0.05), and the observation group was more obvious than the control group (P<0.05). During treatment, no serious adverse reactions occurred in both groups. Conclusions Atorvastatin combined with trimetazidine treatment of coronary heart disease angina pectoris stasis syndrome efficacy of the exact, safe and reliable, may be associated with an effective increase in serum SOD activity, lower serum MDA levels.